ES2187646T3 - Procedimientos para el tratamiento de inflamaciones y composiciones correspondientes. - Google Patents

Procedimientos para el tratamiento de inflamaciones y composiciones correspondientes.

Info

Publication number
ES2187646T3
ES2187646T3 ES96909862T ES96909862T ES2187646T3 ES 2187646 T3 ES2187646 T3 ES 2187646T3 ES 96909862 T ES96909862 T ES 96909862T ES 96909862 T ES96909862 T ES 96909862T ES 2187646 T3 ES2187646 T3 ES 2187646T3
Authority
ES
Spain
Prior art keywords
serp
treatment
compositions
inflammations
procedures
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96909862T
Other languages
English (en)
Inventor
D Grant Mcfadden
Alexandra Lucas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viron Therapeutics Inc
Original Assignee
Viron Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viron Therapeutics Inc filed Critical Viron Therapeutics Inc
Application granted granted Critical
Publication of ES2187646T3 publication Critical patent/ES2187646T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Manufacture And Refinement Of Metals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SE PROPORCIONAN COMPOSICIONES Y METODOS PARA EL TRATAMIENTO DE LA INFILTRACION CELULAR INFLAMATORIA EN UN TEJIDO DE UN SUJETO MAMIFERO. EL METODO IMPLICA LA ADMINISTRACION DE UNA CANTIDAD TERAPEUTICAMENTE EFICAZ DE SERP-1, ANALOGO DE SERP-1 O UN FRAGMENTO BIOLOGICAMENTE ACTIVO DEL MISMO MEZCLADO CON UN VEHICULO FARMACEUTICAMENTE ACEPTABLE A UN SUJETO QUE NECESITE DE DICHO TRATAMIENTO. SE PROPORCIONAN ASIMISMO ANALOGOS DE SERP-1 BIOLOGICAMENTE ACTIVOS. LAS COMPOSICIONES Y METODOS DE LA PRESENTE INVENCION SON UTILES PARA EL TRATAMIENTO DE NUMEROSAS ENFERMEDADES Y LESIONES DE BASE INFLAMATORIA.
ES96909862T 1995-03-27 1996-03-26 Procedimientos para el tratamiento de inflamaciones y composiciones correspondientes. Expired - Lifetime ES2187646T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/411,043 US5939525A (en) 1995-03-27 1995-03-27 Methods of treating inflammation and compositions therefor

Publications (1)

Publication Number Publication Date
ES2187646T3 true ES2187646T3 (es) 2003-06-16

Family

ID=23627329

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96909862T Expired - Lifetime ES2187646T3 (es) 1995-03-27 1996-03-26 Procedimientos para el tratamiento de inflamaciones y composiciones correspondientes.

Country Status (11)

Country Link
US (2) US5939525A (es)
EP (1) EP0817646B1 (es)
JP (1) JPH11503122A (es)
AT (1) ATE230609T1 (es)
AU (1) AU5323396A (es)
CA (1) CA2214988A1 (es)
DE (1) DE69625682T2 (es)
DK (1) DK0817646T3 (es)
ES (1) ES2187646T3 (es)
PT (1) PT817646E (es)
WO (1) WO1996030042A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP508798A0 (en) * 1998-08-05 1998-08-27 Biotech Australia Pty Limited Method of treating psoriasis
ATE297217T1 (de) * 1999-10-27 2005-06-15 Alexandra Lucas Zusammensetzung zur vorbeugung und behandlung von transplantatabstossung
AU1943501A (en) * 1999-12-02 2001-06-12 Viron Therapeutics, Inc. Methods of treating inflammation and compositions therefor
AU6262601A (en) * 2000-05-25 2001-12-03 Ben Williger Phospholipase d effectors for therapy and screening
US7419670B2 (en) * 2000-09-29 2008-09-02 Viron Therapeutics, Inc. Method of treating arthritis with SERP-1 and an immunosuppressant
AU2002211744B8 (en) 2000-10-11 2008-03-20 Viron Therapeutics, Inc. Nucleic acid molecules and polypeptides for immune modulation
EP1339737B1 (en) * 2000-12-04 2007-06-13 Viron Therapeutics, Inc. Immunomodulatory protein derived from the yaba monkey tumor virus
US7718368B2 (en) * 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
CA2440042C (en) * 2001-03-05 2011-09-27 Transtech Pharma, Inc. Carboxamide derivatives as therapeutic agents
WO2004033705A2 (en) * 2001-10-10 2004-04-22 Mount Sinai School Of Medicine Of The City University Of New York Viral interferon antagonists and uses therefor
GB0125594D0 (en) * 2001-10-25 2001-12-19 Univ Sheffield Inhibitors for inactivating allergens
AU2003280252A1 (en) * 2002-11-01 2004-05-25 Alexandra R. Lucas Viral serpin regulation of inflamation
US7285530B2 (en) * 2004-10-21 2007-10-23 Viron Therapeutics, Inc. Use of SERP-1 as an antiplatelet agent
US8251876B2 (en) 2008-04-22 2012-08-28 Hill-Rom Services, Inc. Breathing exercise apparatus
US9180271B2 (en) 2012-03-05 2015-11-10 Hill-Rom Services Pte. Ltd. Respiratory therapy device having standard and oscillatory PEP with nebulizer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206017A (en) * 1986-06-03 1993-04-27 Incyte Pharmaceuticals, Inc. Use of protease nexin-I as an antiinflammatory
ATE146970T1 (de) * 1990-10-16 1997-01-15 John Lezdey Behandlung von entzündungen
WO1992022320A1 (en) * 1991-06-14 1992-12-23 Genentech, Inc. C1 inhibitor variants and treating inflammatory response with c1 inhibitor
DE4214215A1 (de) * 1992-04-30 1993-11-04 Behringwerke Ag Verwendung von inhibitoren von plasminogenaktivatoren zur behandlung von entzuendungen
DK0754054T3 (da) * 1994-04-08 2002-10-14 Viron Therapeutics Inc Antirestenosis-protein

Also Published As

Publication number Publication date
DE69625682D1 (de) 2003-02-13
US5939525A (en) 1999-08-17
WO1996030042A2 (en) 1996-10-03
DK0817646T3 (da) 2003-04-22
WO1996030042A3 (en) 1996-11-21
EP0817646A2 (en) 1998-01-14
ATE230609T1 (de) 2003-01-15
EP0817646B1 (en) 2003-01-08
PT817646E (pt) 2003-04-30
DE69625682T2 (de) 2003-10-02
CA2214988A1 (en) 1996-10-03
US5917014A (en) 1999-06-29
JPH11503122A (ja) 1999-03-23
AU5323396A (en) 1996-10-16

Similar Documents

Publication Publication Date Title
ATE244572T1 (de) Peptid-lipid konjugate, liposomen und liposomale arzneimittelverabreichung
ES2167377T3 (es) Derivados de piridina farmacologicamente activos y procedimientos para la preparacion de los mismos.
AU5323396A (en) Methods of treating inflammation and compositions therefor
LV10180A (lv) Farmaceitiska kompozicija
ES2166783T3 (es) Factor viii activado utilizado como agente terapeutico y metodo para el tratamiento de la deficiencia de factor viii.
UA56989C2 (uk) ФІЗІОЛОГІЧНО АКТИВНИЙ ПЕГ-КОН'ЮГАТ <font face="Symbol">a</font>-ІНТЕРФЕРОНУ, СПОСІБ ЙОГО ОДЕРЖАННЯ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЙОГО ОСНОВІ ТА СПОСІБ ЛІКУВАННЯ АБО ПРОФІЛАКТИКИ ІМУНОМОДУЛЯТОРНИХ ЗАХВОРЮВАНЬ
EP1007556A4 (en) TROPONIN SUB-UNITS AND FRAGMENTS FOR USE AS INHIBITORS OF ANGIOGENESIS
DE69933877D1 (de) Stabiler hypoxie-induzierbarer faktor-1 alpha und verfahren zur verwendung
ES2190472T3 (es) Parche transdermico para la administracion de 17-deacetil norgestimato, solo o en combinacion con un estrogeno.
IL134345A0 (en) Methods for treatment of patients afflicted with multiple sclerosis using consensus interferon
FI971420A0 (fi) Menetelmä diabetes mellituksen hoitamiseksi KGF:ää käyttämällä
AU9157901A (en) Methods of treating inflammatory and immune reactions and compositions therefor
DK0661987T3 (da) Morphogeninduceret leverregeneration
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
ES2111352T3 (es) Uso de diester fosfato para el tratamiento de enfermedades retinianas.
ATE126061T1 (de) Verwendung von lithium zur behandlung oder prophylaxe von molluscum contagiusum.
ATE297217T1 (de) Zusammensetzung zur vorbeugung und behandlung von transplantatabstossung
DE69329760D1 (de) Behandlung von magen- und darmgeschwüren mit morphogenen
BG103512A (en) Substituted pyramidine compounds and their application
US5798392C1 (en) Sulfonyl fluorides for the treatment of alzheimer's disease
ES2169124T3 (es) Acido 4-aminomicofenolico 6-sustituido y derivados con actividad inmunosupresora.
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
AU4918900A (en) Interferon-beta use in the treatment of ewing's family of tumors
MY109685A (en) Method for treating hepatitis b carriers with minimal disease
UA23985A (uk) Спосіб лікуваhhя запальhих захворюваhь вhутрішhіх геhіталій у дівчат та підлітків